Amarin Corporation plc (AMRN)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.4400 |
| Open | 1.4900 |
| Bid | 1.4300 x 39400 |
| Ask | 1.4300 x 3200 |
| Day's Range | 1.3500 - 1.4950 |
| 52 Week Range | 1.1100 - 5.9700 |
| Volume | |
| Avg. Volume | 3,966,290 |
| Market Cap | 562.073M |
| Beta (5Y Monthly) | 2.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0110 |
| Earnings Date | Apr 27, 2022 - May 02, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.61 |
- GlobeNewswire
Amarin Announces Appointment of New Directors and Board Leadership Changes
Erin Enright and Alfonso “Chito” Zulueta Appointed to Board of Directors New Board Members Bring Skills and Experience Aligned with the Company’s Strategy Per Wold-Olsen Named Chairman of the Board David Stack and Joe Zakrzewski to Retire from the Board Actions Reflect Company and Board’s Commitment to Ongoing Refreshment and Enhancement DUBLIN, Ireland and BRIDGEWATER, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced a series of appointments and leader
- GlobeNewswire
Research Presented at the American Heart Association’s Quality of Care and Outcomes Research (QCOR) Scientific Sessions Indicate Potential for VASCEPA® (icosapent ethyl) to Reduce Major Adverse Cardiovascular (CV) Events and Associated Costs
DUBLIN, Ireland and BRIDGEWATER, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that research on the potential population health impact and cost-effectiveness of VASCEPA® (icosapent ethyl), presented in two poster presentations at the American Heart Association’s Quality of Care and Outcomes Research Scientific Sessions in Reston, VA, May 13-14, 2022, showcased significant potential to reduce major cardiovascular (CV) events and associated costs. The
- Zacks
New Strong Sell Stocks for May 13th
DDD, AMRN, and BDX have been added to the Zacks Rank #5 (Strong Sell) List on May 13, 2022.
